MCEMP1 and gastric cancer: C19ORF59 has been reported as a potential therapeutic biomarker associated with immune infiltration in the advanced gastric cancer microenvironment.[40] In the FPMTB cohort, our analysis also reveals that C19ORF59 plays a pivotal role in modulating FLT3i sensitivity (Figure S12, Supporting Information).